<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426112</url>
  </required_header>
  <id_info>
    <org_study_id>QA698</org_study_id>
    <nct_id>NCT02426112</nct_id>
  </id_info>
  <brief_title>Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children</brief_title>
  <acronym>BREATHE</acronym>
  <official_title>Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Research and Training Institute, Zimbabwe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malawi-Liverpool-Wellcome Trust Clinical Research Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tromso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic pulmonary disease (CLD) is the most common manifestation of HIV/AIDS among children,&#xD;
      accounting for more than 50% of HIV-associated mortality. Recently, a novel form of CLD,&#xD;
      affecting more than 30% of African HIV-infected older children was described by Ferrand et al&#xD;
      in Zimbabwe, high-resolution CT scanning findings showed predominantly small airways disease&#xD;
      consistent with constrictive obliterative bronchiolitis (OB). . Azithromycin has&#xD;
      anti-inflammatory activity and treatment of CLD with this agent may lead to suppression of&#xD;
      generalized immune activation.&#xD;
&#xD;
      This specific aims of this project are to:&#xD;
&#xD;
        1. Primary objective: To investigate whether adjuvant treatment with azithromycin results&#xD;
           in improvement in lung function in HIV-infected children with chronic lung disease, who&#xD;
           are stable on antiretroviral therapy.&#xD;
&#xD;
        2. Secondary objectives:&#xD;
&#xD;
             1. To investigate the intervention effect on mortality, exacerbations of lung disease,&#xD;
                quality of life, morbidity.&#xD;
&#xD;
             2. To investigate adverse events related to azithromycin treatment&#xD;
&#xD;
      In total, 400 children aged 6-16 years, living with HIV and diagnosed with CLD will be&#xD;
      enrolled at Harare ChildrenÂ´s Hospital in Harare (Zimbabwe) and Queen Elizabeth Central&#xD;
      Hospital in Blantyre (Malawi). These will receive weekly treatment with azithromycin or&#xD;
      placebo during 12 months. Another 100 children (50 per site) living with HIV but with no CLD&#xD;
      will be enrolled as a comparison group for laboratory sub-studies.&#xD;
&#xD;
      Lung function will be assess using spirometry and the Forced expiratory volume in the first&#xD;
      minute (FEV1) will be the primary outcome. The mean change in FEV1 z-score levels will be&#xD;
      compared between trial arms after 12 months of initiation of azithromycin treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical Phase: III&#xD;
&#xD;
      Trial Design: Multi-site, individually randomised, double-blinded, placebo-controlled trial&#xD;
      of weekly azithromycin for 12 months&#xD;
&#xD;
      Trial Participants: Children aged 6-16 years living with HIV and with diagnosis of chronic&#xD;
      lung disease. Another 200 children living with HIV but with no chronic lung disease in a&#xD;
      comparison arm.&#xD;
&#xD;
      Planned Sample Size: 400 cases and 100 in the comparison arm&#xD;
&#xD;
      Treatment duration: 12 months&#xD;
&#xD;
      Follow up duration: 18 months&#xD;
&#xD;
      Planned Trial Period: June 2016-September 2019&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  Primary trial outcome: To investigate whether adjuvant treatment with azithromycin&#xD;
           results in improvement in lung function in HIV-infected children with chronic lung&#xD;
           disease, who are stable on antiretroviral therapy.&#xD;
&#xD;
        -  Secondary trial outcomes:&#xD;
&#xD;
      .To investigate the intervention effect on mortality,exacerbations of lung disease, quality&#xD;
      of life and morbidity..&#xD;
&#xD;
      .To investigate adverse events related to azithromycin treatment. .-Laboratory sub-studies&#xD;
      .To determine the effect of azithromycin therapy on antimicrobial resistance in bacteria&#xD;
      colonizing the respiratory tract.&#xD;
&#xD;
      .To investigate the diversity and composition of the respiratory microbiome in HIV-infected&#xD;
      children with CLD.&#xD;
&#xD;
      .To investigate the diversity and composition of the gut microbiome in HIV-infected children&#xD;
      with CLD.&#xD;
&#xD;
      .To investigate the effect of azithromycin on biomarkers of systemic inflammation in&#xD;
      HIV-infected children with CLD.&#xD;
&#xD;
      .-Cardiac sub-study: .Describe the cardiac symptoms and echocardiograph findings of&#xD;
      HIV-infected children with chronic lung disease.&#xD;
&#xD;
      .To investigate whether adjuvant treatment with azithromycin results in improvement in&#xD;
      right-sided cardiac function and/or pulmonary hypertension in HIV-infected children with&#xD;
      chronic lung disease.&#xD;
&#xD;
      Investigational Medicinal Product(s): Azithromycin and placebo.&#xD;
&#xD;
      Formulation:Tablets 250 mg&#xD;
&#xD;
      Dose: According to weight bands (30 mg/kg/week):&#xD;
&#xD;
        -  10-20 kg: 250 mg&#xD;
&#xD;
        -  20-29 kg: 500 mg&#xD;
&#xD;
        -  30-39 kg: 750 mg&#xD;
&#xD;
        -  40-49 kg: 1250 mg&#xD;
&#xD;
      Route of Administration:Oral&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in one second z score (FEV1)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in FEV1after 12 months of initiation of therapy with azithromycin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in one second z score (FEV1)</measure>
    <time_frame>24 months</time_frame>
    <description>Mean change in FEV1 24 months after treatment initiation with azithromycin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>12 months</time_frame>
    <description>Time to death 12 months after treatment initiation with azithromycin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first acute exacerbation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of exacerbations</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scores</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in weight-for-age z-score</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mild, moderate and severe adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Malaria episodes (Malawi only)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blood stream infections due to Salmonella typhi and non-typhi</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of gastroenteritis episodes</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Macrolide resistance</measure>
    <time_frame>12 months</time_frame>
    <description>Prevalence of colonization with macrolide (and multidrug-resistant) Streptococcus pneumoniae, Staphylococcus aureus and Haemophilus influenzae in the two trial arms at 12 months of initiation of treatment with azithromycin</description>
  </other_outcome>
  <other_outcome>
    <measure>Lung microbiome</measure>
    <time_frame>baseline, 12 and 14 months</time_frame>
    <description>Composition and diversity of the respiratory bacterial microbiome (determined by culture of clinically relevant organisms and sequencing of 16s rRNA gene amplicons)</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut microbiome</measure>
    <time_frame>baseline, 12 and 24 months</time_frame>
    <description>Composition and diversity of the gut bacterial microbiome (determined by culture of clinically relevant organisms and sequencing of 16s rRNA gene amplicons</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammation biomarkers</measure>
    <time_frame>baseline, 12 and 24 months</time_frame>
    <description>Association between inflammation biomarker levels and FEV1</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac dysfunction</measure>
    <time_frame>Baseline</time_frame>
    <description>prevalence of right sided cardiac dilatation and dysfunction</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac dysfunction after treatment</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Prevalence of right sided cardiac dilatation and dysfunction at 12 and 24 months of initiation of azithromycin therapy by intervention arm</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">347</enrollment>
  <condition>Chronic Lung Disease</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Azithomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azithromycin tablets 250 mg, 30mg/kg/week by mouth, once a week for 12 months.&#xD;
10-20 kg: 250 mg&#xD;
20-29 kg: 500 mg&#xD;
30-39 kg: 750 mg&#xD;
40-49 kg: 1250 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets 250 mg, 30 mg/kg/week by mouth, once a week for 12 months.&#xD;
10-20 kg: 250 mg&#xD;
20-29 kg: 500 mg&#xD;
30-39 kg: 750 mg&#xD;
40-49 kg: 1250 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <arm_group_label>Azithomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of chronic lung disease (defined as FEV1 and/or FVC &lt;80% predicted)&#xD;
&#xD;
          2. Age 6-19 years&#xD;
&#xD;
          3. Perinatally-acquired HIV infection the most likely source of transmission&#xD;
&#xD;
          4. On first or second-line ART for at least one year&#xD;
&#xD;
          5. HIV-1 viral load undetectable (as defined by each trial site)&#xD;
&#xD;
          6. A firm home address accessible for visiting and intending to remain there for 24&#xD;
             months&#xD;
&#xD;
          7. Willing to agree to participate in the study and to give samples of blood and sputum&#xD;
&#xD;
          8. HIV status disclosed to child for those aged older than 12 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition (except HIV) that may prove fatal during the study period (e.g.&#xD;
             malignancy, end-stage HIV disease or other conditions deemed likely fatal by the trial&#xD;
             physician)&#xD;
&#xD;
          2. Diagnosis of active pulmonary TB&#xD;
&#xD;
          3. Infection with non-tuberculous mycobacteria (NTM)&#xD;
&#xD;
          4. Pregnant or breast-feeding&#xD;
&#xD;
          5. Condition likely to lead to lack of understanding of study procedures or to&#xD;
             uncooperative behaviour e.g. neurocognitive disease, developmental delay or&#xD;
             psychiatric illness&#xD;
&#xD;
          6. History of prolonged QTc syndrome or current or planned therapy with drugs likely to&#xD;
             cause cardiac dysrhythmias&#xD;
&#xD;
          7. Abnormal ECG findings&#xD;
&#xD;
          8. Acute respiratory tract infection during enrolment (patients will be eligible once&#xD;
             their acute infection is treated)&#xD;
&#xD;
          9. Creatinine clearance of &lt;30mls/minute&#xD;
&#xD;
         10. ALT more than 2 times the upper limit of normal&#xD;
&#xD;
         11. No defined guardian/stable caregiver&#xD;
&#xD;
         12. No consent/assent from guardian/child&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rashida Ferrand</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon O Odland</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tromso</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malawi-Liverpool-Wellcome Trust Clinical Research Programme</name>
      <address>
        <city>Blantyre</city>
        <zip>30096</zip>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedical Research and Training Institute</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

